Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) have been assigned an average rating of “Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $80.63.
A number of research firms have weighed in on PCRX. TheStreet downgraded Pacira BioSciences from a “b-” rating to a “c” rating in a report on Thursday, February 24th. HC Wainwright lifted their price objective on Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 25th. Northland Securities upped their target price on shares of Pacira BioSciences from $61.00 to $67.00 in a report on Tuesday, March 1st. StockNews.com initiated coverage on shares of Pacira BioSciences in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Wedbush restated a “buy” rating and issued a $94.00 price target (down from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th.
In other news, Director Mark Froimson sold 1,000 shares of the business’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $59.37, for a total transaction of $59,370.00. Following the completion of the sale, the director now owns 4,908 shares in the company, valued at $291,387.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Anthony Molloy sold 22,500 shares of the business’s stock in a transaction on Wednesday, April 6th. The stock was sold at an average price of $76.42, for a total value of $1,719,450.00. Following the sale, the insider now owns 17,550 shares of the company’s stock, valued at approximately $1,341,171. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,607 shares of company stock worth $5,092,865. Insiders own 5.20% of the company’s stock.
Shares of NASDAQ PCRX traded up $0.55 during trading hours on Friday, reaching $63.59. The stock had a trading volume of 351,717 shares, compared to its average volume of 541,323. The business’s fifty day moving average is $72.02 and its two-hundred day moving average is $64.78. The company has a debt-to-equity ratio of 1.03, a current ratio of 2.19 and a quick ratio of 1.85. The company has a market cap of $2.89 billion, a price-to-earnings ratio of 75.70 and a beta of 0.88. Pacira BioSciences has a twelve month low of $45.05 and a twelve month high of $82.16.
Pacira BioSciences (NASDAQ:PCRX – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.64 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.19). The business had revenue of $157.99 million for the quarter, compared to the consensus estimate of $155.08 million. Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. Pacira BioSciences’s revenue was up 32.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.37 earnings per share. Sell-side analysts forecast that Pacira BioSciences will post 2.95 earnings per share for the current fiscal year.
About Pacira BioSciences (Get Rating)
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
- Get a free copy of the StockNews.com research report on Pacira BioSciences (PCRX)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.